The global market for SGLT2 inhibitors treatment is poised for significant growth, with sales projected to reach USD 83,737.4 million by 2034, up from an estimated USD 34,099.3 million in 2024. The market is expected to grow at a compound annual growth rate (CAGR) of 13.2% over the forecast period, driven by the increasing prevalence of diabetes and the broadening applications of these drugs in treating other health conditions.
In 2023, the global revenue generated by SGLT2 inhibitors treatment was USD 30,123.1 million, underscoring the rapid uptake of these drugs in addressing not only type 2 diabetes but also providing cardiovascular and renal benefits. Initially developed for managing type 2 diabetes, SGLT2 inhibitors have proven to offer significant advantages in cardiovascular health, further extending their therapeutic reach.
The growth of the SGLT2 inhibitors market is further fueled by the introduction of combination therapies, which enhance treatment efficacy and improve clinical outcomes. Additionally, newer generations of SGLT2 inhibitors are being developed, promising to expand the range of treatment options available to healthcare providers and patients alike.
“The expanding use of SGLT2 inhibitors, particularly in cardiovascular and renal care, reflects a growing recognition of their multifaceted therapeutic potential,” said FMI. “As research and development continue, we expect the SGLT2 inhibitors market to be a key player in the evolving landscape of chronic disease management.”
This surge in demand for SGLT2 inhibitors is not only transforming diabetes care but also shaping the future of integrated therapies for multiple chronic conditions. As a result, pharmaceutical companies are focusing on advancing their SGLT2 inhibitors portfolio, paving the way for enhanced patient outcomes and long-term market growth.
Key Takeaways:
- The global market for SGLT2 inhibitors treatment is expected to grow significantly, with sales projected to increase from USD 34,099.3 million in 2024 to USD 83,737.4 million by 2034, reflecting a robust compound annual growth rate (CAGR) of 13.2% over the forecast period.
- In 2023, the global revenue from SGLT2 inhibitors treatment reached USD 30,123.1 million, demonstrating a strong base for future growth.
- USA: The market in the USA is anticipated to grow at a moderate CAGR of 2.8% from 2024 to 2034.
- Germany: Expected to experience a CAGR of 2.9% during the forecast period.
- France: The French market is forecasted to show a higher growth rate, with a 4.3% CAGR.
- UK: Sales in the UK are projected to grow at a CAGR of 3.5%.
- China: China is poised for rapid growth, with a notable 10.9% CAGR.
- India: India is expected to exhibit the highest growth rate, with a projected CAGR of 11.5%.
- South Korea: South Korea is anticipated to see a solid CAGR of 8.7% over the same period.
- The significant growth in emerging markets, particularly in India and China, is expected to drive the overall expansion of the SGLT2 inhibitors market.
Rising Interest in Market Trends: Our Detailed Report Provides Essential Insights!
Competitive Landscape:
The SGLT2 inhibitors treatment market is characterized by intense competition, with a diverse mix of players ranging from major pharmaceutical giants to innovative biotech companies. This competitive dynamic is driven by ongoing advancements in drug development, strategic partnerships, and a growing focus on expanding therapeutic indications.
Recent Industry Developments in the SGLT2 Inhibitors Treatment Market
- On July 20, 2024, Eli Lilly and Company unveiled a novel combination therapy that pairs SGLT2 inhibitors with GLP-1 receptor agonists. This new treatment aims to improve glycemic control and support weight management for patients with type 2 diabetes.
- In June 2024, AstraZeneca plc launched an advanced next-generation SGLT2 inhibitor, designed with enhanced renal protective effects. Positioned as a significant improvement over existing treatments, the drug addresses the critical unmet needs in managing chronic kidney disease in diabetic patients.
Key Players of SGLT2 Inhibitors Treatment Industry:
- Eli Lilly and Company (The USA)
- C.H. Boehringer Sohn AG & Ko. KG (Germany)
- Johnson & Johnson (The USA)
- AstraZeneca plc (UK)
- The Merck Group (Germany)
- Pfizer Inc. (The USA)
- Tecnimede Group (The USA)
- Unichem Laboratories Ltd. (India), and
- Edifício Bluepharma (Portugal).
Key Segments of SGLT2 Inhibitors Treatment Industry:
By Product:
In terms of product, the industry is divided into single cap and double cap
By End User:
In terms of end user, the industry is segregated into hospitals, clinics, diagnostic centre’sand others
By Region:
Key countries of North America, Latin America, Europe, East Asia, South Asia & Pacific, Middle East and Africa (MEA) have been covered in the report.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube